Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00005033
Status:
COMPLETED
Last Update Posted:
2013-06-21
First Post:
2000-04-06
Brief Title:
Trastuzumab in Treating Patients With Recurrent Osteosarcoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Study of Recombinant Humanized Monoclonal Antibody Against HER2 for the Treatment of Recurrent Osteosarcoma
Status:
COMPLETED
Status Verified Date:
2004-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells
PURPOSE Phase II trial to study the effectiveness of trastuzumab in treating patients who have recurrent osteosarcoma
PURPOSE Phase II trial to study the effectiveness of trastuzumab in treating patients who have recurrent osteosarcoma
Detailed Description:
OBJECTIVES
Determine the response rate freedom from progression and survival of patients with recurrent osteosarcoma when treated with trastuzumab Herceptin
Evaluate the toxicity of this drug in young patients with a history of osteosarcoma and prior therapy with doxorubicin
OUTLINE This is a multicenter study
Patients receive trastuzumab Herceptin IV over 30-90 minutes weekly Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity After approximately 12 weeks of treatment patients are evaluated for response and undergo surgical resection if clinically appropriate
Patients are followed for 1 year for survival
PROJECTED ACCRUAL Approximately 20-40 patients will be accrued for this study within 2 years
Determine the response rate freedom from progression and survival of patients with recurrent osteosarcoma when treated with trastuzumab Herceptin
Evaluate the toxicity of this drug in young patients with a history of osteosarcoma and prior therapy with doxorubicin
OUTLINE This is a multicenter study
Patients receive trastuzumab Herceptin IV over 30-90 minutes weekly Treatment continues for up to 52 weeks in the absence of disease progression or unacceptable toxicity After approximately 12 weeks of treatment patients are evaluated for response and undergo surgical resection if clinically appropriate
Patients are followed for 1 year for survival
PROJECTED ACCRUAL Approximately 20-40 patients will be accrued for this study within 2 years
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-T98-0083 | None | None | None |
| MSKCC-99097 | None | None | None |